Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").
ESS, previously known as PermaDerm® is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.
DioGenix has preliminary data that suggests our technical approach to MS can be expanded to better understand and improve decision making in other neurological and neurodegenerative diseases, including: Neuro-sarciod, Neuromyelitis optica, Paraneoplastic disease and Lupus with neurological involvement. For further information, please visit www.Amarantus.com, or connect with the company in Facebook, Twitter, LinkedIn & Google+
|PRESS RELEASES & NEWS ARTICLES |
Amarantus Diagnostics - First-Mover Advantage in the $3B Alzheimer’s Blood Test Market with a Business Strategy for Significant Near-Term Revenue in Multiple Sclerosis to Bridge the Gap
January 28th, 2015
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
Jan. 22, 2015
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Jan. 13, 2015
Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix
Jan. 12, 2015
Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
Jan. 8, 2015
Jason Napodano - 15 Biotech Names For 2015
Jan. 5, 2015
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
Dec. 29, 2014
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Dec. 23, 2014
Amarantus Receives Orphan Drug Designation for MANF in Retinitis Pigmentosa
December 23, 2014
Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Market
Dec. 22, 2014
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
Dec. 22, 2014
Amarantus Announces Second Closing of Series E Preferred Financing
Dec. 19, 2014
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
Dec. 19, 2014
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
Dec. 11, 2014
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
Dec. 8, 2014
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
Nov. 25, 2014
Developing an Accurate Test for Multiple Sclerosis Mar 5, 2014
December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.
Oct. 19, 2014
Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
c/o ICS Corporate Services SA
29 quai du Mont Blanc
Phone: (408) 737-2734
Fax: (408) 852-4427
| |Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
Gerald's email address
| | "Amarantus is aiming to be first to market with an accurate, reliable and commercially- viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community by the year-end 2014. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B"
| |“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen” Finally, the company's Alzheimer's blood diagnostic LymPro Test® is slated to become the world's first effective Alzheimer's blood test, expected to establish a market leading position under the Clinical Laboratory Improvement Amendments, and will be available before the end of 2014 for Investigational Use Only to assist the biopharmaceutical industry in its therapeutic Alzheimer's development programs."
| Gerald E. Commissiong - We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value. |
| Click here: On January 13, 2015, Amarantus BioScience Holdings, Inc. (the “Company”) entered into an Exclusive Option Agreement (the “Agreement”) with the Georgetown University (“Georgetown”) pursuant to which the Company was granted an option (the “Option”) to obtain an exclusive license (with the right to sublicense) from Georgetown based upon certain patented technologies entitled “BLOOD BASED BIOMARKERS FOR MEMORY LOSS” (the “Technologies”). The term of the option is 12 months (the “Term”) which may be extended mutual written consent of the parties. In consideration for the grant of the option, the Company shall pay an option fee of $75,000. |
| Amarantus BioScience Participate in the Bio CEO & Investor Coference |
Feb. 10, 2015 at 8:30-8:55 a.m. 4th Floor Trevena Conference Room
Hotel Venue The Waldorf Astoria New York 301 Park Avenue New York, NY 10022
Now in its 17th year,the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
BIO’s One-on-One Partnering™ System is the interactive environment that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide. Using the system, companies are able to: • Pre-schedule 30-minute private 1x1 meetings • Source potential collaborations and funding opportunities with an international audience • Communicate directly with prospective investors and C-level executives in biotech and pharma • Search company and investor profiles for potential business partnerships
BIO will be previewing its next generation Partnering System, intended to launch at the 2015 BIO International Convention. To learn more, visit us at the partnering desk during the BIO CEO & Investor Conference.